Compare ETJ & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETJ | KMDA |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 567.4M | 460.3M |
| IPO Year | 2007 | 2013 |
| Metric | ETJ | KMDA |
|---|---|---|
| Price | $8.40 | $8.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 111.2K | ★ 114.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.88 | $6.50 |
| 52 Week High | $9.12 | $9.35 |
| Indicator | ETJ | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 71.22 |
| Support Level | $8.22 | $8.00 |
| Resistance Level | $8.56 | $8.55 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 22.92 | 97.44 |
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.